Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

DOI: 10.1016/j.cell.2022.06.005

Authors: Aekkachai Tuekprakhon (Wellcome Centre for Human Genetics, University of Oxford) , Jiandong Huo (Wellcome Centre for Human Genetics, University of Oxford) , Rungtiwa Nutalai (Wellcome Centre for Human Genetics, University of Oxford) , Aiste Dijokaite-Guraliuc (Wellcome Centre for Human Genetics, University of Oxford) , Daming Zhou (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Helen M. Ginn (Diamond Light Source) , Muneeswaran Selvaraj (Wellcome Centre for Human Genetics, University of Oxford) , Chang Liu (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Alexander J. Mentzer (Wellcome Centre for Human Genetics, University of Oxford; Oxford University Hospitals NHS Foundation Trust) , Piyada Supasa (Oxford University Hospitals NHS Foundation Trust) , Helen M. E. Duyvesteyn (The Wellcome Centre for Human Genetics, University of Oxford) , Raksha Das (Wellcome Centre for Human Genetics, University of Oxford) , Donal Skelly (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research) , Thomas G. Ritter (Oxford University Hospitals NHS Foundation Trust) , Ali Amini (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research) , Sagida Bibi (University of Oxford) , Sandra Adele (Oxford University Hospitals NHS Foundation Trust) , Sile Ann Johnson (Oxford University Hospitals NHS Foundation Trust) , Bede Constantinides (University of Oxford) , Hermione Webster (University of Oxford) , Nigel Temperton (University of Kent and Greenwich Chatham Maritime) , Paul Klenerman (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; NIHR Oxford Biomedical Research Centre) , Eleanor Barnes (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; NIHR Oxford Biomedical Research Centre) , Susanna J. Dunachie (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; NIHR Oxford Biomedical Research Centre) , Derrick Crook (University of Oxford) , Andrew J. Pollard (University of Oxford; NIHR Oxford Biomedical Research Centre) , Teresa Lambe (Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Philip Goulder (Peter Medawar Building for Pathogen Research; University of Oxford) , Neil G. Paterson (Diamond Light Source) , Mark A. Williams (Diamond Light Source) , David R. Hall (Diamond Light Source) , Elizabeth E. Fry (Wellcome Centre for Human Genetics, University of Oxford) , Juthathip Mongkolsapaya (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Jingshan Ren (The Wellcome Centre for Human Genetics, University of Oxford) , David I. Stuart (Diamond Light Source) , Gavin R. Screaton (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Christopher Conlon (ISARIC4C consortium) , Alexandra Deeks (ISARIC4C consortium) , John Frater (ISARIC4C consortium) , Lisa Frending (ISARIC4C consortium) , Siobhan Gardiner (ISARIC4C consortium) , Anni Jämsén (ISARIC4C consortium) , Katie Jeffery (ISARIC4C consortium) , Tom Malone (ISARIC4C consortium) , Eloise Phillips (ISARIC4C consortium) , Lucy Rothwell (ISARIC4C consortium) , Lizzie Stafford (ISARIC4C consortium)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Cell

State: Published (Approved)
Published: June 2022
Diamond Proposal Number(s): 27009

Abstract: The Omicron lineage of SARS-CoV-2, first described in November 2021, spread rapidly to become globally dominant and has split into a number of sub-lineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa’s Gauteng region uncovered two new sub-lineages, BA.4 and BA.5 which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences and, although closely related to BA.2, contain further mutations in the receptor binding domain of spike. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by serum from triple AstraZeneca or Pfizer vaccinated individuals compared to BA.1 and BA.2. Furthermore, using serum from BA.1 vaccine breakthrough infections there are likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.

Diamond Keywords: Covid-19; Viruses

Subject Areas: Biology and Bio-materials, Medicine


Instruments: I03-Macromolecular Crystallography

Added On: 10/06/2022 10:18

Documents:
1-s2.0-S0092867422007103-main.pdf

Discipline Tags:

Vaccines Pathogens Infectious Diseases Health & Wellbeing Structural biology Life Sciences & Biotech

Technical Tags:

Diffraction Macromolecular Crystallography (MX)